Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479671 · ClinicalTrials.gov registry record · Early Phase 1
Low Dose Fat-Induced Insulin Resistance
A Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03479671 is a Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance that has completed, run by University of Pennsylvania. The registered enrollment target is 9 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03479671, a Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to determine the dose of fatty acids that acutely induces mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid infusion that reliably causes mild insulin resistance will be selected for use in future studies.
Conditions Studied
Interventions
- DRUG Intralipid, 20% Intravenous Emulsion
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2024-11-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03479671
The ClinicalTrials.gov registry entry for NCT03479671 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Intralipid, 20% Intravenous Emulsion is the first listed.
NCT03479671 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03479671 about?
NCT03479671 is a clinical study titled "Low Dose Fat-Induced Insulin Resistance". The primary goal of this study is to determine the dose of fatty acids that acutely induces mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid infusion that reliably ca...
What is the current status of trial NCT03479671?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2020-01-01. Estimated completion is 2024-11-19.
What conditions does trial NCT03479671 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity.
What interventions are being tested in trial NCT03479671?
The interventions under investigation include: Intralipid, 20% Intravenous Emulsion (DRUG).
Who is sponsoring clinical trial NCT03479671?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03479671 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I
COMPLETED · Early Phase 1
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.